InvestorsHub Logo
Followers 107
Posts 10872
Boards Moderated 0
Alias Born 06/26/2007

Re: JBZ post# 149158

Friday, 10/07/2022 10:01:28 AM

Friday, October 07, 2022 10:01:28 AM

Post# of 155558
The Company recently acquired five generic oncology drugs approved and manufactured in Germany and they plan to gain approval for these drugs in the US in 2023. The Company is preparing for a pivotal Phase 3 study of an anti-cancer antibody product that is highly similar to Genentech/Roche's brand name Avastin (bevacizumab), and the Company is in the pre-clinical stages of development of a gene therapy product candidate based on the delivery of a human alpha-Klotho gene and protein to prevent and/or treat neurodegenerative diseases such as Alzheimer's and Lou Gehrig's disease (ALS). Other product candidates will stem from these platform technologies of pharmaceuticals, biologics, and gene therapy.